Agreements

Date: 2017-12-21

Type of information: Exercise of an option agreement

Compound: tumour-associated peptide (TUMAP)-based cancer vaccine (including IMA942) and other cancer immunotherapies

Company: immatics biotechnologies (Germany) Roche (Switzerland)

Therapeutic area: Cancer - Oncology

Type agreement: R&D - research - development - commercialisation

Action mechanism:

immunotherapy product. XPRESIDENT® technology platform is centered on the identification of target peptides expressed and presented on the cell surface of tumor cells and not on the cell surface of normal tissue. The cancer targets identified by XPRESIDENT® are peptides presented by human leukocyte antigen (HLA) receptors on the surface of tumor cells.

Disease: gastric cancer, prostate cancer, non-small cell lung cancer

Details:

• On November 13, 2013, immatics biotechnologies and Roche have announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics. The agreement will focus on the research, clinical development and commercialisation of a number of new tumour-associated peptide (TUMAP)-based cancer vaccine candidates and other immunotherapies in oncology, targeting primarily gastric, prostate and non-small cell lung cancer. The most advanced cancer vaccine candidate covered by the agreement is IMA942, for the treatment of gastric cancer, which is ready for phase I trials. Roche will be responsible for the clinical development and commercialisation of all of the immunotherapies generated by immatics as a result of this collaboration.
In parallel with the clinical development of IMA942 by Roche, immatics will conduct research on behalf of Roche using its unique XPRESIDENT® technology platform to identify novel and relevant TUMAP candidates for the development of cancer vaccines and other compounds targeting cancer peptide antigens, primarily in gastric, prostate and non-small cell lung cancer. The XPRESIDENT® discovery platform is to date the only known high-throughput research technology to directly identify, quantify, and prioritize cancer antigens recognized by T lymphocytes (type of white blood cell) based on the ability of the immune system to detect them.

Financial terms:

Under the terms of the agreement, immatics will receive an upfront payment of $17 million and committed research funding plus potential milestone payments that could reach values in excess of $1 billion and royalties across three cancer indications, based on sales of the cancer vaccines and immunotherapies resulting from this agreement.

Latest news:

• On December 21, 2017, Immatics announced that Roche has exercised its option under their existing discovery, development and commercialization agreement.The target was identified and validated using Immatics’ world-leading XPRESIDENT® technology platform. Successful development and subsequent commercialization of cancer immunotherapies directed against this target would trigger payment of additional development and sales milestones by Roche to Immatics, as well as royalty payments on worldwide net sales.